Literature DB >> 26048916

Quantitative assessment of CD30+ lymphocytes and eosinophils for the histopathological differential diagnosis of inflammatory bowel disease.

Cristina Flores1, Carlos Fernando Francesconi2, Luíse Meurer2.   

Abstract

BACKGROUND AND AIMS: The histopathological discrimination of Crohn's disease [CD] and ulcerative colitis [UC] can be challenging. The aim of this study was to evaluate if quantification of CD30(+) lymphocytes and eosinophils in histopathological material improves the accuracy of diagnosis of inflammatory bowel disease.
METHODS: A total of 156 patients were diagnosed with IBD by a gastroenterologist and corroborated by 5 years of follow-up. Patients were treatment naïve at the time of biopsy. Samples were taken from diseased areas of the colon and examined by a gastrointestinal pathologist.
RESULTS: The median number of eosinophils in biopsies from affected segments was 42/high power field [hpf] [25.5-63.5] in CD and 98/hpf [67-123] in UC [p < 0.001]. Biopsies containing ≥ 70 eosinophils/hpf field had a sensitivity of 78.3% and a specificity of 71% for the diagnosis of UC ({area under the receiver operating characteristic (ROC) curve 0.767 (95% confidence interval [CI] 0.696-0.838)}. There was a median of three CD30(+) cells/hpf [range 2-6] in diseased CD biopsies and 33 cells/hpf [24-52] in diseased UC biopsies [p < 0.001]. The cut-off determined by the ROC curve was 15 (sensitivity 97.4%, specificity 97.4%, positive likelihood ratio (PLR) 17.1, Negative likelihood ratio (NLR) 0.03, area under the curve [AUC]: 0.978; 95% CI 0.95310.999).
CONCLUSIONS: Routine histopathological assessment with quantification of CD30+ cells is highly accurate at discriminating CD and UC. All the measured parameters are easy to perform, low-cost, and available in most pathological laboratories.
Copyright © 2015 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Inflammatory bowel disease; eosinophils; immunohistochemistry

Mesh:

Substances:

Year:  2015        PMID: 26048916     DOI: 10.1093/ecco-jcc/jjv097

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  7 in total

1.  Colonic hypereosinophilia in ulcerative colitis may help to predict the failure of steroid therapy.

Authors:  Giuseppe Leoncini; Vincenzo Villanacci; Maria Grazia Marin; Valentina Crisafulli; Moris Cadei; Elisabetta Antonelli; Claudio Leoci; Gabrio Bassotti
Journal:  Tech Coloproctol       Date:  2018-12-10       Impact factor: 3.781

2.  Concise Commentary: Calling in Your Marker-Rectal CD30-Positive Cells Differentiate Ulcerative Colitis from Crohn's Disease.

Authors:  Mathieu Uzzan
Journal:  Dig Dis Sci       Date:  2018-07       Impact factor: 3.199

3.  De novo inflammatory bowel disease after pediatric kidney or liver transplant.

Authors:  Melissa A Fernandes; Hillary J Braun; Kim Evason; Sue Rhee; Emily R Perito
Journal:  Pediatr Transplant       Date:  2016-11-11

4.  Immunohistochemical Assessment of CD30+ Lymphocytes in the Intestinal Mucosa Facilitates Diagnosis of Pediatric Ulcerative Colitis.

Authors:  Ondrej Fabian; Ondrej Hradsky; Tereza Drskova; Filip Mikus; Josef Zamecnik; Jiri Bronsky
Journal:  Dig Dis Sci       Date:  2018-03-14       Impact factor: 3.199

5.  CD30 expression and survival in extranodal NK/T-cell lymphoma: a systematic review and meta-analysis.

Authors:  Zihang Chen; Pujun Guan; Tong Shan; Yunxia Ye; Limin Gao; Zhi Wang; Sha Zhao; Wenyan Zhang; Li Zhang; Ling Pan; Weiping Liu
Journal:  Oncotarget       Date:  2018-01-08

6.  Quantitative Analysis of Distribution of the Gastrointestinal Tract Eosinophils in Childhood Functional Abdominal Pain Disorders.

Authors:  Eun Hye Lee; Hye Ran Yang; Hye Seung Lee
Journal:  J Neurogastroenterol Motil       Date:  2018-10-01       Impact factor: 4.924

7.  Diagnostic Potential of Systemic Eosinophil-Associated Cytokines and Growth Factors in IBD.

Authors:  Katarzyna Neubauer; Malgorzata Matusiewicz; Iwona Bednarz-Misa; Sabina Gorska; Andrzej Gamian; Malgorzata Krzystek-Korpacka
Journal:  Gastroenterol Res Pract       Date:  2018-07-29       Impact factor: 2.260

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.